Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29634588 | 1.00 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5634995 | 0.98 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9383598 | 0.91 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| Isopropylamine SCHEMBL28069314 | 0.89 | HTR2A (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL38657587 | 0.88 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31285028 | 0.87 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31285041 | 0.87 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| Propylamine SCHEMBL27607874 | 0.86 | ADRA1A (0.56) | CA12CA1CA2CA7CA9 | |
| Dimethylformamide SCHEMBL28323288 | 0.84 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5057198 | 0.83 | CA12 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253623-B | Direct cross-coupling method of aryl fluorine sulfate and aryl bromine | 南京工业大学 | 2024-04-05 | — | — | CN | claimed |
| CN-116554378-A | Non-metallocene catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-112174800-B | Preparation method of 2, 5-dimethoxy phenylacetic acid | 爱斯特（成都）生物制药股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-116253623-A | Direct cross-coupling method of aryl fluorine sulfate and aryl bromine | 南京工业大学 | 2023-06-13 | — | — | CN | claimed |
| US-20220416316-A1 | Flame Retardants For Battery Electrolytes | ALBEMARLE CORPORATION | 2022-12-29 | — | — | US | claimed |
| CN-114685251-B | Direct cross-coupling reaction method of diaryl sulfoxide and aryl bromide | 南京工业大学 | 2022-12-27 | — | — | CN | claimed |
| EP-4062479-A1 | FLAME RETARDANTS FOR BATTERY ELECTROLYTES | ALBEMARLE CORPORATION (US) | 2022-09-28 | — | — | EP | claimed |
| CN-114685251-A | Direct cross-coupling reaction method of diaryl sulfoxide and aryl bromide | 南京工业大学 | 2022-07-01 | — | — | CN | claimed |
| CN-114667630-A | Flame retardant for battery electrolytes | 雅宝公司 | 2022-06-24 | — | — | CN | claimed |
| CN-113387876-B | Nickel-catalyzed direct reduction cross-coupling method for heterocyclic phosphonium salt and aryl bromide and product | 南京工业大学 | 2022-04-15 | — | — | CN | claimed |
| CN-110112414-A | A kind of novel anode material, preparation method and applications | 欧格尼材料科技江苏有限公司 | 2019-08-09 | — | — | CN | claimed |
| CN-103456982-A | Functional electrolyte for improving charge-discharge efficiency of lithium ion battery and application thereof | CHINA NAT OFFSHORE OIL CORP | 2013-12-18 | — | — | CN | claimed |
| CN-102718800-A | 3,7-di(diphenylphosphino oxyl)-2,6-diphenyl benzo difuran derivative, preparation method thereof and organic electroluminescent device | OCEANS KING LIGHTING SCIENCE | 2012-10-10 | — | — | CN | claimed |
| EP-2275099-A1 | Treatment of faecal incontinence with 1r,2s-methoxamine | Norgine Europe BV (NL) | 2011-01-19 | — | — | EP | claimed |
| US-20050096397-A1 | Treatment of faecal incontinence and other conditions with 1r,2s-methoxamine | NORGINE EUROPE BV (NL) | 2005-05-05 | — | — | US | claimed |
| EP-1458370-A1 | TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R,2S-METHOXAMINE | Norgine Europe BV (NL) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055474-A1 | TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R, 2S-METHOXAMINE | NORGINE EUROPE BV (NL) | 2003-07-10 | — | — | WO | claimed |
| US-6355826-B1 | HALOMETHYLATION AN AROMATIC ALDEHYDE COMPOUND AND SALT FORMATION | THE GOODYEAR TIRE & RUBBER COMPANY | 2002-03-12 | — | — | US | claimed |
| EP-0903338-A2 | Synthesis of stable nitrile oxide compounds | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1999-03-24 | — | — | EP | claimed |
| US-4940807-A | Selective bromination of aromatic compounds using potassium tribromide | ETHYL CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096397-A1 | Treatment of faecal incontinence and other conditions with 1r,2s-methoxamine | HTR1D, MTNR1A, ADRA1D | CA12 4359/4885CA1 4525/4885CA2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.